文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

骨髓纤维化异基因移植后完全供者嵌合:预处理方案的作用

Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen.
PubMed 文献 · Am J Hematol · 2020-11-30

该回顾性研究分析120例骨髓纤维化患者,比较含一种或两种烷化剂预处理后第+30天完全供者嵌合(F-DC)率。TBF组(两种烷化剂)第+30天F-DC率为87%,ONE-ALK组为45%(P<.001);TBF组5年累积复发率9% vs 43%(P<.001),5年无病生存率63% vs 38%(P=.004)。

要点

  • 含两种烷化剂的TBF预处理较单烷化剂方案显著提高第+30天完全供者嵌合率。
  • TBF组5年累积复发率显著低于单烷化剂组,5年无病生存率显著更高。
  • 早期完全供者嵌合是骨髓纤维化异基因移植后长期疾病控制的前提。

核心结论

  • 早期完全供者嵌合是骨髓纤维化患者接受异基因造血干细胞移植后长期控制疾病的先决条件。
  • 含两种烷化剂的预处理方案有更高机会在第+30天达到完全供者嵌合,从而有更高机会获得长期无病生存。

研究设计与样本

  • 回顾性研究,分析120例骨髓纤维化患者,均有第+30天嵌合数据。
  • 42例接受一种烷化剂(塞替派或白消安或美法仑)联合氟达拉滨预处理(ONE-ALK组)。
  • 78例接受两种烷化剂塞替派、白消安联合氟达拉滨预处理(TBF组)。

主要发现

  • TBF组较ONE-ALK组患者年龄更大(57 vs 52岁),移植前脾切除比例更低(31% vs 59%)。
  • TBF组较ONE-ALK组中危-2/高危DIPSS评分比例更高(90% vs 74%),替代供者移植比例更高(83% vs 33%),移植前芦可替尼使用比例更高(26% vs 7%)。
  • 第+30天完全供者嵌合比例:TBF组87% vs ONE-ALK组45%(P < .001)。
  • 5年累积复发率:TBF组9% vs ONE-ALK组43%(P < .001)。
  • 5年无病生存率:TBF组63% vs ONE-ALK组38%(P = .004)。

临床怎么用

  • 对骨髓纤维化异基因移植患者,可考虑含两种烷化剂的TBF预处理以提高第+30天完全供者嵌合率。
  • 第+30天完全供者嵌合可作为长期疾病控制的早期预测指标。

局限性

  • 回顾性研究设计。
  • 两组基线特征不平衡:TBF组年龄更大、DIPSS评分更高、替代供者比例更高、移植前芦可替尼使用更多、脾切除更少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this retrospective study was to assess the rate of full donor chimerism (F-DC) in patients with myelofibrosis, prepared for an allogeneic stem cell transplant, with one or two alkylating agents. We analyzed 120 patients with myelofibrosis, for whom chimerism data were available on day +30. There were two groups: 42 patients were conditioned with one alkylating agent (ONE-ALK), either thiotepa or busulfan or melphalan, in combination with fludarabine, whereas 78 patients were prepared with two alkylating agents, thiotepa busulfan and fludarabine (TBF). Patients receiving TBF were older (57 vs 52 years), were less frequently splenectomized pre-HSCT (31% vs 59%), had more frequently intermediate-2/high DIPSS scores (90% vs 74%), were grafted more frequently from alternative donors (83% vs 33%) and received more frequently ruxolitinib pre-HSCT (26% vs 7%). The proportion of patients with F-DC on day +30, in the TBF vs the ONE-ALK group, was respectively 87% vs 45% (P < .001). The 5-year cumulative incidence of relapse was 9% in the TBF group, vs 43% for the ONE-ALK group (P < .001). The 5-year actuarial disease-free survival was 63% for TBF and 38% for the ONE-ALK group (P = .004). In conclusion, early full donor chimerism is a prerequisite for long term control of disease in patients with myelofibrosis, undergoing an allogeneic HSCT. The combination of two alkylating agents in the conditioning regimen, provides a higher chance of achieving full donor chimerism on day+30, and thus a higher chance of long term disease free survival.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Chiusolo P, Bregante S, Giammarco S, et al. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. Am J Hematol. 2020. PMID: 33146914. doi:10.1002/ajh.26042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。